Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector

Molecular Therapy : the Journal of the American Society of Gene Therapy
J E McCormackJ Greengard

Abstract

We have studied parameters affecting in vivo expression of human growth hormone (hGH) in mice after intravenous administration of a retroviral vector encoding the protein as a model system for clotting factor VIII gene therapy. Such treatment results in a brief burst of high-level expression followed by lower level sustained expression of the hGH in the circulation. The major targets for transduction in the mouse are liver and spleen. Such direct transduction (i.e., without surgical or chemical induction of cell division) requires vector at high titer (>/=10(8) cfu/ml) and is dose dependent. Transduction efficiency decreases with increasing age of the recipient. Nevertheless, long-term expression in adults is observed after administration of vector as a split dose on 2 consecutive days. We also show that anti-vector immune responses may enhance long-term expression and that both anti-vector and anti-transgene immunity can be modulated. This work provides a framework for the rational development of means to enhance the efficiency of retroviral vectors for use in clinical gene replacement therapy.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y DaiI M Verma
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·N FerryJ M Heard
Jan 1, 1990·Methods in Enzymology·S M Jazwinski
Jun 1, 1990·DNA and Cell Biology·G ZettlmeisslB Seed
Aug 1, 1986·Molecular and Cellular Biology·A D Miller, C Buttimore
May 1, 1971·The American Journal of Physiology·W P WebsterG D Penick
Nov 18, 1983·Science·R D PalmiterR L Brinster
Feb 10, 1997·Human Gene Therapy·T J RussiR G Crystal
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A KayC B Wilson
Jul 1, 1997·Human Gene Therapy·J E McCormackJ Warner
Jun 24, 1998·The Journal of Clinical Investigation·S R CaiK P Ponder
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·T VandenDriesscheM K Chuah
Sep 25, 1999·Human Gene Therapy·R J Kaufman
Dec 28, 1999·Human Gene Therapy·S A RosenbergN A Habib
Apr 25, 2000·Human Gene Therapy·R SarkarH H Kazazian
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Sep 14, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·C GaoK P Ponder

❮ Previous
Next ❯

Citations

Nov 5, 2003·Brain Research. Molecular Brain Research·Stephanos KyrkanidesHoward J Federoff
Oct 13, 2005·Human Gene Therapy·Alessandra Biffi, Luigi Naldini
Mar 1, 2007·International Journal of Older People Nursing·Tina KochDebbie Kralik
Feb 16, 2008·British Journal of Haematology·Samuel L Murphy, Katherine A High
Dec 18, 2007·The Journal of Gene Medicine·Anna BaoutinaKerry R Emslie
Feb 16, 2005·Brain Research. Molecular Brain Research·Stephanos KyrkanidesHoward J Federoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.